AbbVie Hails Humira’s Resistance To US Competition
Adalimumab Originator Does Better Than Expected Against Biosimilar Pressure In Q2
As the firm reported Q2 results, AbbVie management offered some insights into how Humira is standing up against US biosimilar adalimumab competition a little better than expected.
